AXGN
Price
$58.63Alerts
Change
+$7.74 (+15.21%)
Updated
Nov 11 closing price
Capitalization
2.93B
103 days until earnings call
Intraday BUY SELL Signals
ECOR
Price
$7.71Alerts
Change
-$0.01 (-0.13%)
Updated
Nov 11 closing price
Capitalization
65.37M
119 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AXGN vs ECOR

AXGN vs ECOR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AXGN vs. ECOR commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXGN is a Buy and ECOR is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for AXGN with price predictions
Nov 11, 2026

AXGN in +15.78% Uptrend, growing for three consecutive days on November 11, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where AXGN advanced for three days, in 266 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on AXGN as a result. In 68 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for AXGN just turned positive on October 20, 2026. Looking at past instances where AXGN's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.

AXGN moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for AXGN crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

AXGN broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for AXGN entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.452) is normal, around the industry mean (4.142). P/E Ratio (-74.657) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.080) settles around the average of (0.011) among similar stocks. P/S Ratio (8.961) is also within normal values, averaging (40.124).

The Tickeron Profit vs. Risk Rating rating for this company is 11 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. AXGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for ECOR with price predictions
Nov 11, 2026

ECOR in +21.71% Uptrend, rising for three consecutive days on November 05, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ECOR advanced for three days, in 240 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ECOR's RSI Indicator exited the oversold zone, 17 of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for ECOR just turned positive on November 04, 2026. Looking at past instances where ECOR's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ECOR as a result. In 79 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

ECOR moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ECOR crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ECOR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

ECOR broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ECOR entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ECOR's P/B Ratio (-23.428) is slightly lower than the industry average of (4.142). P/E Ratio (-4.394) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.571) is also within normal values, averaging (40.124).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. ECOR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ECOR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
AXGN vs ECOR: Fundamental Ratings
AXGN
ECOR
OUTLOOK RATING
1..100
469
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
18
Undervalued
PROFIT vs RISK RATING
1..100
11100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
3560
P/E GROWTH RATING
1..100
7871
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AXGN's Valuation (4) in the Medical Specialties industry is in the same range as ECOR (18). This means that AXGN’s stock grew similarly to ECOR’s over the last 12 months.

AXGN's Profit vs Risk Rating (11) in the Medical Specialties industry is significantly better than the same rating for ECOR (100). This means that AXGN’s stock grew significantly faster than ECOR’s over the last 12 months.

AXGN's SMR Rating (95) in the Medical Specialties industry is in the same range as ECOR (100). This means that AXGN’s stock grew similarly to ECOR’s over the last 12 months.

AXGN's Price Growth Rating (35) in the Medical Specialties industry is in the same range as ECOR (60). This means that AXGN’s stock grew similarly to ECOR’s over the last 12 months.

ECOR's P/E Growth Rating (71) in the Medical Specialties industry is in the same range as AXGN (78). This means that ECOR’s stock grew similarly to AXGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AXGNECOR
RSI
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
81%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 7 days ago
86%
Declines
ODDS (%)
Bearish Trend 16 days ago
82%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
85%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (AXGN: $50.89 vs. ECOR: $7.72)
Brand notoriety: AXGN and ECOR are both not notable
Both companies represent the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: AXGN: 65% vs. ECOR: 97%
Market capitalization -- AXGN: $2.93B vs. ECOR: $65.37M
AXGN [@Medical/Nursing Services] is valued at $2.93B. ECOR’s [@Medical/Nursing Services] market capitalization is $65.37M. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $190.22B. The average market capitalization across the [@Medical/Nursing Services] industry is $6.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AXGN’s FA Score shows that 2 FA rating(s) are green while ECOR’s FA Score has 1 green FA rating(s).

  • AXGN’s FA Score: 2 green, 3 red.
  • ECOR’s FA Score: 1 green, 4 red.
According to our system of comparison, AXGN is a better buy in the long-term than ECOR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AXGN’s TA Score shows that 5 TA indicator(s) are bullish while ECOR’s TA Score has 4 bullish TA indicator(s).

  • AXGN’s TA Score: 5 bullish, 5 bearish.
  • ECOR’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, AXGN is a better buy in the short-term than ECOR.

Price Growth

AXGN (@Medical/Nursing Services) experienced а +2.81% price change this week, while ECOR (@Medical/Nursing Services) price change was +6.78% for the same time period.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.

Reported Earning Dates

AXGN is expected to report earnings on Feb 23, 2027.

ECOR is expected to report earnings on Mar 11, 2027.

Industries' Descriptions

@Medical/Nursing Services (-2.89% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

AXGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AXGN has been loosely correlated with XRAY. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if AXGN jumps, then XRAY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AXGN
1D Price
Change %
AXGN100%
+15.21%
XRAY - AXGN
36%
Loosely correlated
+0.62%
KIDS - AXGN
34%
Loosely correlated
+0.57%
ITGR - AXGN
31%
Poorly correlated
+0.05%
GMED - AXGN
31%
Poorly correlated
+0.21%
ICUI - AXGN
30%
Poorly correlated
-2.11%
More

ECOR and

Correlation & Price change

A.I.dvisor tells us that ECOR and SENS have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ECOR and SENS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ECOR
1D Price
Change %
ECOR100%
-0.13%
SENS - ECOR
30%
Poorly correlated
+3.89%
QDEL - ECOR
29%
Poorly correlated
+3.39%
PFSA - ECOR
28%
Poorly correlated
+0.18%
AXGN - ECOR
26%
Poorly correlated
+15.21%
EW - ECOR
26%
Poorly correlated
+1.73%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FFND31.740.26
+0.83%
One Global ETF (FFND)
ROPE31.470.19
+0.59%
Coastal Compass 100 ETF
BAY26.96N/A
N/A
Corgi Bay Area Based ETF (BAY)
ISVL52.26-0.03
-0.05%
iShares International Developed Small Cap Value Factor ETF (ISVL)
FREL29.44-0.05
-0.17%
Fidelity MSCI Real Estate Index ETF (FREL)